The significantly lower expression of cyclin D1 in BRG1-defient NSCLC cells compared with BRG1-intact normal control cells makes cyclin D1 as well as CDK4/6 proteins potential synthetic lethal targets for the treatment of NSCLC [91]. The gene discussed is SMARCA4; the disease is non-small cell lung carcinoma.